2. Academic Validation
  3. Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice

Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice

  • Parasitology. 2020 Nov;147(13):1425-1432. doi: 10.1017/S0031182020001225.
G Vural 1,  M Yardimci 2,  M Kocak 3,  T Ö Yasar 4,  A Kurt 5,  I S Harem 6,  S Carradori 7,  I Sciamanna 8,  M Siles-Lucas 9,  M Fabiani 10,  A Hemphill 11,  B Lundström-Stadelmann 11,  R Cirilli 12,  A Casulli 13 14
Affiliations

Affiliations

  • 1 Department of Parasitology, Veterinary Faculty, Namik Kemal University, Tekirdağ, Turkey.
  • 2 Department of Biostatistics, Veterinary Faculty, Namik Kemal University, Tekirdağ, Turkey.
  • 3 Histology and Embryology Department, Veterinary Faculty, Namik Kemal University, Tekirdağ, Turkey.
  • 4 Department of Surgery, Veterinary Faculty, Namik Kemal University, Tekirdağ, Turkey.
  • 5 Pathology Laboratory, University of Health Science, Erzurum Regional Education and Research Hospital, Erzurum, Turkey.
  • 6 Department of Histology-Embryology, Veterinary Faculty, Harran University, Şanlıurfa, Turkey.
  • 7 Deparetment of Pharmacology, Università 'G. D'Annunzio' di Chieti-Pescara, Chieti, Italy.
  • 8 National Centre for Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
  • 9 Parasitology Unit, Instituto de Recursos Naturales y Agrobiología de Salamanca, IRNASA-CSIC, Salamanca, Spain.
  • 10 Unit of Epidemiology, Biostatistics and Mathematical Modelling, Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • 11 Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, Institute of Parasitology, University of Bern, Bern, Switzerland.
  • 12 National Centre for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy.
  • 13 Department of Infectious Diseases, WHO Collaborating Centre for the Epidemiology, Detection and Control of Cystic and Alveolar Echinococcosis, Istituto Superiore di Sanità, Rome, Italy.
  • 14 European Reference Laboratory for Parasites (EURLP), Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
PMID: 32729453 DOI: 10.1017/S0031182020001225
Abstract

In this study, we evaluated the efficacy, expressed as a mean weight decrease of the whole echinococcal cyst mass, of novel benzimidazole salt formulations in a murine Echinococcus granulosus Infection model. BALB/c mice were intraperitoneally infected with protoscoleces of E. granulosus (genotype G1). At 9 months post-infection, treatment with albendazole (ABZ), ricobendazole (RBZ) salt formulations, and RBZ enantiomer salts (R)-(+)-RBZ-Na and (S)-(-)-RBZ-Na formulations were initiated. Drugs were orally applied by gavage at 10 mg kg-1 body weight per day during 30 days. Experimental treatments with benzimidazole sodium salts resulted in a significant reduction of the weight of cysts compared to conventional ABZ treatment, except for the (S)-(-)-RBZ-Na enantiomer formulation. Scanning electron microscopy and histological inspection revealed that treatments impacted not only the structural integrity of the Parasite tissue in the germinal layer, but also induced alterations in the laminated layer. Overall, these results demonstrate the improved efficacy of benzimidazole salt formulations compared to conventional ABZ treatment in experimental murine cystic echinococcosis.

Keywords

Albendazole; Echinococcus granulosus; efficacy; enantiomers; mouse model; new formulations; ricobendazole; salts of benzimidazoles; salts of ricobendazole; secondary cystic echinococcosis.

Figures
Products